Literature DB >> 1554498

Inherited deficiencies of the terminal components of human complement.

R Würzner1, A Orren, P J Lachmann.   

Abstract

The particularly frequent occurrence of terminal complement deficiencies in patients with Neisserial infections suggests that the cytolytic activity of the complement system is important in resistance to Neisseria meningitidis. There are, however, geographical differences in the prevalence of terminal complement deficiency in patients with meningococcal disease. The data available suggest that either recurrent infection or infection with uncommon serogroups should alert the clinician in Western countries whereas recurrent disease is the important indicator in high risk endemic or epidemic areas. An association of terminal complement deficiencies with susceptibility to autoimmune diseases or non-Neisserial infections is doubtful. For a better understanding of complement deficiencies in relation to disease more accurate characterization of the defects involved will be helpful. Sensitive ELISA techniques and molecular biological assays will be needed. Thus it has been established that two types of deficiencies exist (at least for C6, C7 and C8): one with low but detectable amounts of the component and the other with a complete absence of the protein in question. The subtotal variety appears to show less association with Neisserial infection. Low amounts of functional terminal complement activity may be sufficient for many of its biological functions, suggesting that there is a wide "safety margin".

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554498

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN: 0893-5300


  25 in total

Review 1.  Molecular mechanisms of complement component C6 deficiency; a hypervariable exon 6 region responsible for three of six reported defects.

Authors:  A Orren
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  An abnormal but functionally active complement component C9 protein found in an Irish family with subtotal C9 deficiency.

Authors:  Ann Orren; Ann M O'Hara; B Paul Morgan; Anthony P Moran; Reinhard Würzner
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

Review 3.  Deficiencies of the complement MAC II gene cluster (C6, C7, C9): is subtotal C6 deficiency of particular evolutionary benefit?

Authors:  R Würzner
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 4.  Vaccination against meningococcus in complement-deficient individuals.

Authors:  B P Morgan; A Orren
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

5.  How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion.

Authors:  R Würzner; A E Platonov; V B Beloborodov; A I Pereverzev; I V Vershinina; B A Fernie; M J Hobart; P J Lachmann; A Orren
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

6.  Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9.

Authors:  A M O'Hara; A P Moran; R Würzner; A Orren
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

7.  Two novel mutations in the C7 gene in a Korean patient with complement C7 deficiency.

Authors:  Chang-Seok Ki; Jong-Won Kim; Hee-Jin Kim; Sung-Min Choi; Gyoung-Yim Ha; Hee Jung Kang; Won-Duck Kim
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

Review 8.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

9.  C7 deficiency in an Irish family: a deletion defect which is predominant in the Irish.

Authors:  A M O'Hara; B A Fernie; A P Moran; Y E Williams; J J Connaughton; A Orren; M J Hobart
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 10.  Complement and glomerulonephritis--an update.

Authors:  R H McLean
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.